Commentary · 21 Feb 2026
Conference abstractPublished 13 Jun 2016
The role of Epo/EpoR signaling pathway in colorectal cancer
Clinical Hospital Center Rijeka, Croatia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Colorectal cancer (CRC) is a heterogeneous disease with increasing incidence and is the third most common cancer worldwide. 80% of CRC cases are sporadic without family history or genetic predisposition as a result of agglomeration of mutations and epigenetic modifications of several genes together with environmental factors. Chemotherapy together with targeted drugs tending to individualized therapy is a cornerstone of systemic treatment. Molecular and genetic features of the tumor determine the prognosis and response to (targeted) treatments. Anemia of chronic disease can be found in about 60-70% of patients with malignant disease. Pathophysiology of this type of anemia is multifactorial and level of hemoglobin is independent bad prognostic factor for survival. Anemia in malignant disease is often cured with recombinant erythropoietin (rHuEpo). Epo is a 34 kDa glycoprotein hormone, which binds to cells with erythropoietin receptor (EpoR), thus leading to its activation and stimulation of erythropoiesis. EpoR is a protein, member of the cytokine receptor family, where expression was found in different tumors. The role of Epo/EpoR signaling pathway in CRC remains unclear and data from studies are inconclusive. Moreover, the data in vivo are not consistent with those in vitro suggesting that Epo in vivo is probably acting together with other growth factors. Because there is still no conclusive answer about whether rHuEpo therapy leads to tumor progression, clinicians can use it only in limited frameworks. Especially precaution must be taken using rHuEpo together with anticancer drugs which are using activation of NF-kB to kill cancer cells due to association of Epo and protein NF-kB in apoptotic resistance, thus leading to negative effect of anticancer therapy. For elucidating the role of Epo/EpoR system in CRC and other tumors, standard procedures for detection of receptor-specific antibodies, for binding of radiolabeled ligands and confirmation of receptor size at the appropriate molecular mass must be followed. Even after such a use with all precautions, limitations in these techniques can possibly lead to a contradictory and inconclusive data.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Renata Dobrila-Dintinjana”
